Edition:
India

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

63.91USD
19 Jan 2018
Change (% chg)

$0.41 (+0.65%)
Prev Close
$63.50
Open
$63.51
Day's High
$64.36
Day's Low
$62.26
Volume
396,794
Avg. Vol
286,455
52-wk High
$192.94
52-wk Low
$59.86

Select another date:

Sat, Jan 13 2018

BRIEF-Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion

* TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION

BRIEF-Tesaro secures $500 million non-dilutive term loan financing

* Tesaro secures $500 million non-dilutive term loan financing

BRIEF-Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

* Tesaro announces European Commission approval of Zejula for women with recurrent ovarian cancer

BRIEF-Tesaro reports Q3 loss per share $0.47

* Q3 revenue $142.8 million versus I/B/E/S view $132.8 million

BRIEF-Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea, vomiting associated with chemotherapy

* Opko Health licensee Tesaro announces FDA approval of Varubi IV for delayed nausea and vomiting associated with chemotherapy

BRIEF-Evotec, Tesaro enter partnership on novel immuno-oncology agents

* dgap-news: evotec and tesaro enter strategic partnership to discover novel immuno-oncology agents

FDA approves intravenous version of Tesaro drug for chemotherapy nausea

Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.

FDA approves intravenous version of Tesaro drug for chemotherapy nausea

Oct 25 Tesaro Inc said on Wednesday that the U.S. Food and Drug Administration approved an intravenous version of its drug to treat chemotherapy-induced nausea and vomiting in adults.

Tesaro's ovarian cancer drug gets EU agency backing

A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.

Tesaro's ovarian cancer drug gets EU agency backing

Sept 15 A European Medicines Agency (EMA) panel recommended the approval of Tesaro Inc's key drug, niraparib, for the treatment of recurrent ovarian cancer.

Select another date: